WELCOME TO QATAR PHARMACY EST . . . . مرحبا بكم في مؤسسة صيدلية قطر

Retail Outlets

IBN KHALDOON PHARMACY IBN HAYAN PHARMACY DIPLOMAT PHARMACY QATAR PHARMACY TARGET MEDICAL EQUIPMENT CENTRAL QATAR PHARMACY FARLIN BABY SHOP

VISITORS

9 3 8 1 2

PO Box 390

Doha - Qatar

Phone: + 974 44320887

Fax : + 974 44320933

info@qatarpharmacyest.com



ask our pharmacist

staff login
logo

SPIMACO ADDWAEIH

SPIMACO ADDWAEIH

Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) is a Saudi Joint–Stock company with a fully paid-up capital of SR 784,375,000 . It was established in 1986 . SPIMACO Addwaeih’s core business is medical and pharmaceutical, which includes development, manufacturing and sales of pharmaceutical products and medical appliances. Moreover, SPIMACO also has ownership in number of joint stock ans limited liabilities companies inside and outside the Kingdom . SPIMACO has developed a strong position in Saudi Arabia and is well positioned to sustain its growth and have a sound platform to serve export markets.SPIMACO main manufacturing facility – Al–Qassim Pharmaceutical Plant was planned , constructed and equipped up to the highest quality levels. SPIMACO earned a lot of national quality awards and attained major international certifications.SPIMACO serves successfully several markets locally and internationally and have built superior relations with regulatory bodies and the medical professions at large. The heavy investments in regulatory, marketing, sales and international alliances gave SPIMACO the market capabilities to prosper and overtake a lot of competitors.An important and distinctive advantage of SPIMACO strategy is its relations with multinational companies. A very flexible, objective and versatile approach let to a multitude of relationships that served the interests of all parties.SPIMACO is a successful joint stock company and it has one of the most actively traded shares in the Saudi stock market.WEBSITE:   http://www.spimaco.com.sa/

The local SPIMACO staff can be contacted by dialing +974 44320887 Extn. 23.

logo

Alcon

Alcon

Improving Vision through Innovation Since 1945 Alcon was founded in 1945 as a small ophthalmic shop in Fort Worth, Texas. View our timeline to learn how we’ve become the global leader in eye care and the second-largest division of Novartis. Alcon History 1945 Two pharmacists, Robert Alexander and William Conner, open a small pharmacy in Fort Worth, Texas, combining the first syllables of their last names to call it Alcon. 1947 With William Conner as Alcon’s first president, Alcon Laboratories, Inc. is incorporated. The company begins manufacturing specialty pharmaceutical products. Alexander and Conner fill prescriptions during the day, and at night prepare sterile, injectable vitamins and oral products using a blender and pressure cooker. 1950 Alcon introduces its first two ophthalmic products: Ophthalzin™ for minor eye infections and Zincfrin® for red, itchy eyes. 1953 While on a sales call in West Texas, Robert Alexander and a local physician create and patent the DROP-TAINER® eye drop dispensing bottle, now standard for eye care products. 1959 Alcon opens an office in Canada, beginning its international operations. 1962 Alcon begins its patient assistance program, providing free medications to low-income glaucoma patients and supporting medical missions worldwide. 1969 Alcon’s surgical division is formed with seven associates. 1971 With sales of $31 million, Alcon goes public with a listing on the New York Stock Exchange. 1972 Ed Schollmaier assumes the role of president. During his tenure, Alcon sales grow from $36 million to $2 billion and the company becomes the world’s largest ophthalmic company. 1978 Swiss food company Nestlé acquires Alcon. The acquisition provides capital to accelerate Alcon’s global growth and manufacturing expansion. 1979 Alcon begins an ongoing partnership with ORBIS International* to bring eye care services and health care provider training to impoverished communities worldwide. 1982 The William C. Conner Research Center is established, helping Alcon significantly expand research into treatments for eye diseases and disorders. 1988 Alcon acquires Sharpoint, Inc., expanding its surgical manufacturing capabilities. 1989 Alcon purchases CooperVision Surgical and combines them with its existing operations to become the world’s leading ophthalmic surgical company. 1990 Alcon’s Irvine Technology Center, the world’s foremost center for the development of ophthalmic instrumentation, opens in California. 1994 The FDA approves Alcon’s AcrySof® intraocular lens (IOL), representing the first time a material had been developed specifically for an IOL. Today, Alcon’s portfolio of AcrySof® IOLs are the world’s most frequently implanted lenses. 1997 Alcon introduces Patanol® ophthalmic solution, now the leading prescription eye drop for treating allergic conjunctivitis. 1997 Tim Sear, a longtime leader in Alcon’s international expansion, becomes the company’s third president and CEO. 2000 Alcon acquires Summit Autonomous and Grieshaber to enter the refractive laser market and expand its line of retinal surgery instruments. 2000 Alcon introduces OPTI-FREE® EXPRESS®, the world’s first no-rub solution for contact lens disinfection. 2001 Alcon introduces TRAVATAN® ophthalmic solution for lowering intraocular pressure in glaucoma patients. 2002 Alcon offers 25 percent of its shares on the New York Stock Exchange, re-entering the stock market 40 times larger than when it left in 1978. 2003 Alcon launches several flagship products, including Systane® eye drops for the treatment of dry eye symptoms, Vigamox® ophthalmic solution for bacterial conjunctivitis or “pink eye,” CIPRODEX® optic suspension for middle and outer ear infection, and the AcrySof® Natural IOL, which filters UV and blue light. 2004 Cary Rayment, who joined Alcon in 1989 with the CooperVision acquisition, is appointed Alcon’s fourth president and CEO. 2005 Alcon launches the AcrySof® ReSTOR® IOL, which provides a full range of vision. This lens quickly becomes the global leader in multi-focal IOLs. 2006 Alcon significantly expands its glaucoma and cataract treatments with TRAVATAN Z® ophthalmic solution, which lowers intraocular pressure in glaucoma patients and the AcrySof® Toric IOL for cataract patients with astigmatism. 2007 Alcon introduces Pataday™ ophthalmic solution, the first once-a-day prescription eye drop for eye allergy itching. 2007 Alcon expands its product portfolio for LASIK surgery through regulatory clearance to purchase Wavelight AG. 2008 Alcon launches the company’s first nasal product, Patanase® nasal spray, to treat nasal allergy symptoms and AcrySof® line expansions with the Phakic and IQ ReSTOR® +3.0 D IOLs. 2008 Novartis purchases approximately 25 percent of Nestlé’s stake in Alcon, becoming its second largest shareholder. Novartis also retains the option to purchase the remaining 52 percent of Nestlé’s ownership of Alcon beginning in 2010. 2009 Alcon’s leading brand of intraocular lenses (IOLs), AcrySof®, exceeds 40 million implants. 2009 Alcon Laboratories, Inc., the U.S. subsidiary of Alcon, is recognized for the 11th consecutive year as one of FORTUNE’s “Best Companies To Work For.” 2009 Kevin Buehler, who joined the Alcon sales force in 1984, is appointed Alcon’s fifth president and CEO. 2010 Alcon expands its cataract surgical portfolio with the acquisition of LenSx® Laser platform. The innovative laser technology enables surgeons to perform the most delicate manual steps of cataract surgery with image-guided visualization and laser precision. 2011 The boards of Novartis and Alcon complete its merger agreement, giving Novartis 100 percent ownership of Alcon. The merger unites the strengths of Alcon, CIBA Vision and Novartis Ophthalmics into one eye care business, making Alcon the second-largest division of Novartis. Sales reach $10 billion. Alcon commits to a $5 billion investment to discover and develop new and innovative treatments for vision conditions and eye diseases. This represents the largest commitment to research and development in the eye care industry. Alcon launches DAILIES TOTAL1® contact lenses within select European markets. DAILIES TOTAL1® contact lenses are the first and only water gradient contact lenses featuring an increase from 33 percent to over 80 percent water content from core to surface, and with a surface water content that’s nearly the same as the cornea. 2012 Alcon enters into a strategic licensing agreement with ThromboGenics to commercialize ocriplasmin outside the U.S. Ocriplasmin has the potential to become the first pharmacological treatment for vitreomacular traction (VMT) and macular hole. The licensing agreement confirms Alcon’s commitment to bringing innovative eye care treatments to patients with unmet medical needs. Alcon enters into the ophthalmic microscope market through the acquisition of Endure Medical Systems, which specializes in advanced technology surgical microscopes. The LuxOr Ophthalmic Microscope, with applications for both cataract and vitreoretinal surgeries, offers improved intra-operative visualization. To further improve patient outcomes in cataract surgery, Alcon acquires the ophthalmic division of SensoMotoric Instruments, providing Alcon with leading ocular surgical guidance technology. Alcon celebrates its 30-year partnership with ORBIS International*, reaffirming its commitment to restoring sight and eliminating preventable blindness across the globe. * Trademark of Project ORBIS International

logo

PATTERSON MEDICALS)

PATTERSON MEDICALS)

Welcome Inside Patterson MedicalWe are one of the world's leading suppliers of Rehabilitation and Medical Solutions. With keen knowledge of local markets and a strong national and international presence including France, Australia & US, Patterson Medical remains the partner of choice for increasing efficiency and profitability. We have strong partnerships with and distribute products to customers including the NHS and private hospitals, private therapists, local authorities and councils, mobility shops, high street retailers, pharmacists, internet traders and international distributors.Your Future is with Patterson MedicalOver 12,000 products to choose from: We offer one of the largest ranges available including many own manufactured products and exclusive leading brands which are only available from us; this range is constantly being updated and refreshed to meet the changing needs of the customer.Nationwide Delivery: Orders received before 4pm Monday to Friday will be despatched within 24hrs for UK Customers. We offer an unrivalled delivery service from our modern distribution centres located in Nottingham

Rabies Tags

logo

Plethico

Plethico

Plethico Pharmaceuticals Limited is a leading global healthcare / pharmaceutical company with a strong emphasis on the herbal and nutraceuticals segments. The company which was established in 1991 and focused on manufacturing and marketing a range of branded generic pharmaceutical formulations, has rapidly evolved and now engages in the manufacture, marketing and distribution of pharmaceutical and allied healthcare products in the nutraceuticals and herbal segments in India and internationally. Domestically, Plethico operates in the segments of Sports Nutrition, Confectionary and OTC, in India. As per the market research form EuroMonitor, Plethico is globally the 11th largest firm in US $ 5 bn. Sports Nutrition Product Market. The company today has a portfolio of over 200 branded products sold in more than 60 countries

logo

FARLIN

FARLIN

FARLIN has established renowned reputation since 1972, and been cooperating with more than 76 exclusive agents in the world closely for successful sales, as well as producing and selling a top quality line of baby care products, which leads FARLIN to the service of worldwide sales network. FARLIN produces hundreds of various products in accordance with every baby's demand such as: Full range of baby accessories, baby garments,baby carriage, baby playthings...etc.,which provide various choices as well as kind service manner to satisfy per your needs. We have been upholding four main objectives which guide us to rapid market expansion: Keeping continued research and development of ..... innovatory products. Compliance with international standards of safety request. Offering reasonable price. Professional and cordial service. FARLIN products have become the necessity of the families that have ever used. We are sincerely looking forward to taking part of the development & growth of your baby. Let FARLIN take care of your baby with you. The expectation and future of Farlin Approach to doing business,is the journey to serve consumers in an absolutely sole and effective way. This purpose has been communicated to all employees worldwide. Our purpose in Farlin is to meet the everyday needs of baby everywhere

logo

PHARCO

PHARCO

Pharco Pharmaceuticals, the founder of the corporation. Pharco Pharmaceuticals is the second private Egyptian shareholding pharmaceutical company established in 1984 and started production in 1987 formulating,producing and marketing about 237 brands, generics , branded generics and licensed products. Pharco Pharmaceuticals started with the manufacturing of antibiotics under license from Mead Johnson (now known as Bristol-Myers Squibb) and soft gelatin capsules (using RP Scherer technology), in addition to other traditional pharmaceutical forms. These products cover most of the pharmacological groups and all the conventional pharmaceutical dosage forms. Pharco Pharmaceuticals has a separate dedicated facility for manufacturing of sterile and non-sterile Penicillins. Pharco Pharmaceuticals has scientific offices ;KSA,Yemen,UAE,Bahrain,Lebanon,Libya and Romania. Pharco Pharmaceuticals exports to 47 countries. Throughout the years Pharco Pharmaceuticals has created several brands which have become market leaders in both local and international markets; Rani effervescent, Fawar Fruit, Ciprofar 500 MG tablets,Spasmo Digestin, Delcophen amp, Royal jelly, Uricol effervescent, Urinex caps, Bilichol caps, Mirazid and BabyDrink.Pharco Pharmaceuticals is located and head quartered in Amriya, Alexandria, Egypt.

logo

COMFORT

COMFORT

Comfort Orthopedic Co. Ltd was established since the year 1978 in Taiwan. We have always had a policy of combining high quality with innovation. Our products have obtained many awards from "It's very well made in Taiwan" and "Good Design Product." Our company obtained "Rising Star Award", President Lee got the 1985 Model of Youth Career Development of Taiwan., and General Manager Chen received the 2nd annual of "Enterprise Professional Manager Award." We hope to receive more awards in the future. But we do not rest on our laurels. In order to maintain growth, we constantly add to our team of professionals and have extended our factories in Taiwan and China to increase quality levels and customer service. We are therefore proud to announce the creation of a new and more fitting logo to represent from 2003.1.1 The new logo with a more stream line appearance represents a more harmonized, friendly company culture and combines fashion with our products. The slogan "life is just beginning" encourages our company and all our customers to discard bad memories, and plan a new life from now on. We are confident in our ability to present the market place with new high tech products. In the future we guarantee that the trade mark of Comfort represents the best quality and believe our products will bring complete satisfaction to the end user. You will see"Comfort" more and more through out the world, and we welcome you to join us.

logo

CAMBRIDGE SENSORS

CAMBRIDGE SENSORS

Company Founders

 

Mr James McCann - MBA (Harvard University), was one of the co-founders of Medisense Inc which developed and commercialised the first home glucose biosensor during the 1980's. Medisense was bought by Abbott Laboratories for $870M in 1996. James is now the Managing Director of CSL.

 

Dr Chris Lowe - Director of the Institute of Biotechnology (University of Cambridge), runs one of the largest UK academic groups working on Sensors, Chromatography and Biotechnology.

 

Investers / Ownership

 

Cambridge Sensors Limited is independently owned. Major investors include major UK corporations and financial institutions.

logo

ORTHOFIX

ORTHOFIX

Orthofix offers a broad line of diversified products including minimally invasive surgical, as well as non-surgical products for the spine, orthopedic and biologic market sectors. To search our database of innovative orthopedic products and solutions by condition, treatment, area of care and more...

logo

SEDICO

SEDICO

SEDICO Pharmaceuticals Company Our mission: We improve people’s quality of life through providing quality healthcare diverse of productsOur Vision:To be the most trusted biopharmaceutical in the region, through upgrading the quality of our consumers’ life; by offering high value products, and community added value.Our Core Values:TrustSense of Urgency Teamwork ExcellenceOur company:SEDICO is the civilized face of EGYPT in the pharmaceutical industriesSEDICO as a pharmaceutical industry in Egypt is earning encomiums from people across every corner of the world.SEDICO was established in 1989 and started production in 1990.SEDICO pharmaceutical company has been around for quite a while, as years have gone by, it has become better, stronger and looks ahead to the future more confidently.SEDICO typically applies cGMP regulations throughout the operational departments including evaluation of raw materials, calibration of equipments, control, holding and distribution of finished products. SEDICO has managed to stick along, very well. The company has stretched, elongated and diversified into newer therapeutic areas while consolidating the existing ones.SEDICO pharmaceutical products deal with some of the most vital parts of a human system. We will come to that later, meanwhile let’s get a feel of the more vital factors and make out as to what made this company a pretty well known pharmaceutical giant.SEDICO Pharmaceuticals took the responsibility to get the access to a very important & strategic issue which is Human Insulin production in Egypt.SEDICO Pharmaceuticals started the big project of insulin production as a new era of production of Biotechnology products in collaboration with Akzo Nobel Corporation to be the first Egyptian company that formulates human insulin among the very few multinational companies producing insulinSEDICO pharmaceutical produces the different types of Human Insulin in different concentrations.Some of SEDICO pharmaceutical products have given there western equivalents a run for their money and certainly made a wake up call. In addition to this, they have proved to be pillars for the Egyptian consumer’s wellbeing too.SEDICO is unique by its Sterile Areas (which are the largest in the Middle East and North African Region) that are environmentally controlled to obtain filtered air up to 97% - 99.7% particulate-free. The water purification system in SEDICO was designed to supply the production zones with demineralized and distilled water. SEDICO Pharmaceuticals was the Pioneer Egyptian Company to produce the instant products such as: Acetylcistein and Silymarin plus sachets.SEDICO Pharmaceuticals also produces the non-traditional dosage forms such as the soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. The sound management enables SEDICO to seek the highest quality of raw material from the least expensive sources.SEDICO products have been selected according to the actual needs taking into consideration the following priorities: ► New products to replace the imported ones. ► The new technology in pharmaceutical industry and researches. ► The mutual co-operation between the Egyptian experts and researchers at SEDICO and those of the foreign international pharmaceutical companies according to license agreements. Training Courses at SEDICO Pharmaceuticals are of the highest possible level of the pharmaceutical industry. SEDICO Pharmaceuticals has its own Computer Network System of the latest generations connecting all various activities of production, storage and administration to optimize the Q.M.S.SEDICO Pharmaceuticals made License Agreements with a group of International Pharmaceutical Companies to produce their specialties to replace imported products, to cover the increasing demand and to acquire technology and know- how.The production facility just seems to have got better and as to date the company can feel a tinge of pride to being one of the largest and most experienced contract manufacturer for a number of multinational companies naming Organon pharmaceuticals (Akzo-Nobel group), which on the other hand owns 24% of the company’s shares.By the beginning of the new millennium, SEDICO Pharmaceuticals were ready to face one of the most challenging tasks, we started our marvelous project; the 21st Century biotechnology project, to supply the Egyptian patients with a group of products that were difficult to be produced locally in the past, now that dream came to be a truth.SEDICO Pharmaceuticals have succeeded to build one of the most recent and most advanced biotechnology production units in Egypt that stand equally with those of the multinational companies.SEDICO Pharmaceuticals is one of the very few leading Egyptian companies that produce the finest Biotechnology products:SEDICO Pharmaceuticals has strategic alliances with several multinational companies; these strategic alliances have resulted in the spawning of state-of-the-art-facility for Bio-technology products, which includes Insulin, Epoetin.Angikinase: For the lysis of acute massive pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments and for the lysis of pulmonary emboli accompanied by unstable hemodynamics, i.e., failure to maintain blood pressure without supportive measures.Sedonase: Sedonase injection contains a highly purified streptokinase derived from cultural filtrate of beta-hemolytic streptococci of lance field group C. The drug is supplied as a sterile, lyophilized white powder.SEDICO Pharmaceuticals possesses excellent facilities and state-of-the-art manufacturing equipment. On 1996, SEDICO Pharmaceuticals has been awarded the ISO - 9001 Certificate by the (BSI) for establishing, Implementing and maintaining quality assurance systems in Design, Development, Production, Installation and Servicing. On 1998, SEDICO Pharmaceuticals has also been awarded the ISO - 14001 Certificate regarding Environmental - friendly practices. SEDICO Pharmaceuticals is one of the largest local producers of pharmaceuticals products in Egypt.SEDICO Pharmaceuticals exports their pharmaceutical products to Arab Countries, Gulf area, and to some African, and East European Countries.SEDICO Pharmaceuticals pays a great attention to public health care; one of our major issues of interest is diabetes. Arising from that interest, we put a Diabetes center on our website to be a nucleus for focusing our interests in diabetes and as a new service from SEDICO Pharmaceuticals to the public.At SEDICO Pharmaceuticals company we believe that our community has the right to share and benefit from our business success.This belief is clearly depicted in an array of SEDICO programs aiming at satisfying some of the community needs.SEDICO Pharmaceuticals and BSI certificates:► Quality Management System - ISO 9001:2008► Environmental management System - ISO 14001:2004► Occupational Heath & Safety Management System - BS OHSAS 18001:2007SEDICO Pharmaceuticals departments:Production departments:► Semisolid and liquid dosage forms department. ► Solid dosage forms department. ► Sterile liquid dosage forms department. ► Sterile powder dosage forms department. ► Antibiotic powder dosage forms department. ► De-mineralized and distilled water station department. ► Maintenance workshop department.Warehouses sites: ► Receiving ware house department. ► Material storage sites, including: ٭ Raw material storage department. ٭ Packaging material storage department. ٭ Inflammatory materials segregated storage site. ٭ Rejected materials segregated storage site. ٭ Quarantine site. ٭ Finished product site ٭ Dispensing siteQuality departments: ► Chemical Quality Control Laboratories► Biotechnology laboratory► Quality Assurance ► R&D LaboratoriesAssisting engineering facilities departments:► Air condition: Boiler, compressor & air handling unit. ► Electric power generators ► Work shopCommercial department:Dr. Ihab Kaldas (CCO)► Administration of tenders:Responsible: Mr. M.Abdel Aziz EliwaE-mail: tender@SEDICO.net mohamed.eliwa@SEDICO.net►Administration of direct sales:Responsible: Dr. Moataz AbdouEmail: moataz.abdou@SEDICO.net►Marketing Department:Dr.Ashraf Hamdy ashraf.hamdy@SEDICO.net► Biotechnology administrationResponsible: Dr. Ragai Soliman SobhyEmail: ragai.sobhy@SEDICO.net► Export administrationResponsible: Dr. Mohamed Aly Helmy Dr. Mohamed El Menyawi Dr. Mohamed Yamany ► Scientific officesResponsible: Dr. Hesham ShoukryEmail: hesham.shoukry@SEDICO.net Training CenterFinancial Data & Historical DevelopmentProductsResearch and Development Spins around Much Better at SEDICOLooking Beyond the National BoundariesExploration into Newer AreasChairman: Dr. Ahmed Abu el Enein website:www.sedico.net

SEDICO Medical Representative Dr Ali ElLaboudy can be contacted on his mobile +974 33668336 or on his office No. 444178217.

Page12 3 >